Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Nat Genet. 2014 Feb;46(2):176-181. doi: 10.1038/ng.2856. Epub 2013 Dec 22.
Follicular lymphoma is an incurable malignancy, with transformation to an aggressive subtype representing a critical event during disease progression. Here we performed whole-genome or whole-exome sequencing on 10 follicular lymphoma-transformed follicular lymphoma pairs followed by deep sequencing of 28 genes in an extension cohort, and we report the key events and evolutionary processes governing tumor initiation and transformation. Tumor evolution occurred through either a 'rich' or 'sparse' ancestral common progenitor clone (CPC). We identified recurrent mutations in linker histone, JAK-STAT signaling, NF-κB signaling and B cell developmental genes. Longitudinal analyses identified early driver mutations in chromatin regulator genes (CREBBP, EZH2 and KMT2D (MLL2)), whereas mutations in EBF1 and regulators of NF-κB signaling (MYD88 and TNFAIP3) were gained at transformation. Collectively, this study provides new insights into the genetic basis of follicular lymphoma and the clonal dynamics of transformation and suggests that personalizing therapies to target key genetic alterations in the CPC represents an attractive therapeutic strategy.
滤泡性淋巴瘤是一种无法治愈的恶性肿瘤,在疾病进展过程中向侵袭性亚型转化是一个关键事件。在这里,我们对 10 对滤泡性淋巴瘤转化的滤泡性淋巴瘤进行了全基因组或全外显子组测序,然后在扩展队列中对 28 个基因进行了深度测序,并报告了控制肿瘤起始和转化的关键事件和进化过程。肿瘤进化是通过“丰富”或“稀疏”的祖细胞共同前体细胞克隆(CPC)发生的。我们鉴定了连接组蛋白、JAK-STAT 信号、NF-κB 信号和 B 细胞发育基因中的反复突变。纵向分析鉴定了染色质调节基因(CREBBP、EZH2 和 KMT2D(MLL2))中的早期驱动突变,而在转化时获得了 EBF1 和 NF-κB 信号调节因子(MYD88 和 TNFAIP3)的突变。总的来说,这项研究为滤泡性淋巴瘤的遗传基础以及转化的克隆动态提供了新的见解,并表明针对 CPC 中的关键遗传改变进行个体化治疗代表了一种有吸引力的治疗策略。